Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Psychedelic Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The psychedelic drugs sector has experienced swift expansion in recent years, with its market value rising from $6.33 billion in 2025 to an anticipated $7.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This historical growth has been driven by a significant unmet need for effective depression therapies, foundational academic investigations into psychedelics, instances of underground and compassionate use, the constrained effectiveness of traditional antidepressants, and an increasing public focus on mental health.
The psychedelic drugs market is projected to experience rapid expansion over the coming years, reaching an estimated $13.67 billion by 2030 with a compound annual growth rate (CAGR) of 16.7%. This anticipated growth during the forecast period is driven by several key factors: regulatory approvals for medical use, increasing adoption by psychiatrists, a broadening pipeline of therapeutic indications, improved data on patient outcomes, and strategic collaborations between biotechnology firms and healthcare providers. Significant trends shaping this period include the growth of psychedelic-assisted therapy programs, a rising number of clinical trials targeting mental health conditions, greater acceptance of alternative psychiatric approaches, clearer regulatory pathways for controlled substances, and heightened investment from venture capital and pharmaceutical companies.
Download A Free Sample Report For Comprehensive Market Insights:
Psychedelic Drugs Market Expansion Supported By Key Demand Factors
The rising prevalence of mental health disorders is anticipated to drive the expansion of the psychedelic drugs market in the coming period. Mental illnesses are health conditions characterized by alterations in mood, thought processes, or behavior, encompassing issues such as distress and post-traumatic stress disorder (PTSD). Psychedelic drugs are utilized for treating depression and PTSD, with their consistent application contributing to a reduction in mental illness cases. For example, in November 2023, data from the National Health Service, a UK governmental agency, revealed that about one in five individuals aged 8 to 25 had a probable mental disorder that year, representing 20.3% of 8 to 16-year-olds, 23.3% of 17 to 19-year-olds, and 21.7% of 20 to 25-year-olds. Consequently, the growing number of mental illness cases is fueling the growth of the psychedelic drugs market.
Psychedelic Drugs Market Segment Landscape: Which Areas Lead Market Development?
The psychedelic drugs market covered in this report is segmented –
1) By Type: Lysergic Acid Diethylamide (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia
2) By Disease Indication: Depression, PTSD
3) By Origin: Natural, Synthetic
4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders
5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Lysergic Acid Diethylamide (LSD): LSD Tablets, LSD Liquid, LSD Blotters
2) By Ketamine: Ketamine Infusion, Ketamine Nasal Spray, Ketamine Injectable
3) By Phencyclidine (PCP): PCP Powder, PCP Tablets, PCP Liquid
4) By Gamma Hydroxybutyric Acid (GHB): GHB Liquid, GHB Powder, GHB Capsules
5) By Salvia: Salvia Extract, Salvia Dried Leaves, Salvia Tinctures
Psychedelic Drugs Market Growth Trends Influencing Competitive Dynamics
Key players in the psychedelic drugs market are placing increasing emphasis on the creation of pharmaceutical-grade psilocybin formulations, designed to boost therapeutic effectiveness, improve safety profiles, and broaden available treatments for mental health conditions. Such formulations involve psilocybin that is manufactured and calibrated to meet strict pharmaceutical benchmarks, ensuring dependable purity, consistent strength, and safe clinical application. In September 2025, for example, Optimi Health, a psychedelic therapeutics company based in Australia, introduced its natural psilocybin capsules into the Australian market specifically for treating treatment-resistant depression (TRD). Through this introduction, Optimi Health seeks to offer patients a clinically validated therapeutic choice, strengthen its foothold in Australia’s mental health sector, and speed up the wider acceptance of psychedelic-assisted therapeutic approaches.
Psychedelic Drugs Market Industry Leaders And Market Competition
Major companies operating in the psychedelic drugs market are Atai Life Sciences, Cybin Inc., Mind Medicine Inc., Compass Pathways, Seelos Therapeutics, Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation, Beckley Psytech, Awakn Life Sciences, Psygen Industries, Enveric Biosciences, Filament Health, Tactogen, Bexson Biomedical, BetterLife Pharma, Clairvoyant Therapeutics, Universal Ibogaine
Access The Complete Psychedelic Drugs Market Report:
Psychedelic Drugs Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the psychedelic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model